Coherus Biosciences Accounts Payable

The latest accounts payable for CHRS is $11M as of March 2026. That compares with $41M in the prior-year period — down 72.0% year over year. Investors often review this figure alongside Coherus Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CHRS's accounts payable moved from $41M to $11M — a 72.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Coherus Biosciences's operating scale or balance-sheet position.

A accounts payable figure of $11M for CHRS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CHRS's accounts payable ($11M), review year-over-year change from $41M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Coherus Biosciences's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.